Published online by Cambridge University Press: 23 March 2020
Sexual function is important for patients’ well-being but it is acommon side effect of SSRI and SNRI, included desvenlafaxine.
Evaluate incidence and characteristics of sexual dysfunction caused bydesvenlafaxine in the clinical practice.
One hundred and thirty-three patients with recently introduced desvenlafaxinetreatment are recruited from Barakldo and Uribe-Kosta Mental Health Centresin Biscay, Spain. UKU scale is administered to measure sexual side effects.Statistical analysis is performed using SPSS v.22.
Sexual dysfunction is observed in 5 patients (3.7%) at 50 and 100 mg/d (2 and3 patients, respectively) desvenlafaxine doses. Two patients (1.5%) haveexperimented more than one sexual side effect. Regarding gender differences,the most frequent sexual dysfunctions are diminished sexual desire (5.5%)and erectile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) inwomen (P-values are 0.034; 0.034 and 0.408, respectively).Discontinuation is decided in 60% of patients.
Desvenlafaxine has a well-tolerated sexual side effect profile in generalpopulation. There are some gender-related differences both in presentationand perception, as it has been described with other drugs, and this shouldbe taken into account by prescriptors.
The authors have not supplied their declaration of competing interest.
Comments
No Comments have been published for this article.